Related Experiment Video
Updated: Apr 29, 2026
06:39
Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
Published on: October 27, 2023
1.6K
Our 2014 approach to mucormycosis
Daniela Tacke1, Philipp Koehler, Birgid Markiefka
1Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Mycoses
|May 16, 2014
Summary
Early diagnosis and prompt treatment are crucial for combating severe mucormycosis in immunocompromised patients. This study outlines diagnostic and treatment strategies, emphasizing liposomal amphotericin B and surgical debridement for suspected cases.
Area of Science:
- Mycology
- Infectious Diseases
- Immunocompromised Host Management
Background:
- Mucormycosis, a severe fungal infection caused by Mucorales, has high morbidity and mortality, especially in immunocompromised individuals.
- Timely diagnosis and immediate treatment are critical due to the often-unfavorable outcomes.
- Randomized clinical trials are lacking, necessitating clear diagnostic and treatment guidelines.
Purpose of the Study:
- To present current diagnostic and treatment pathways for mucormycosis in immunocompromised hosts.
- To emphasize the importance of considering mucormycosis as a differential diagnosis due to challenges in distinguishing it from other filamentous fungi.
- To provide a practical approach for managing this severe infection.
Main Methods:
- Diagnostic procedures include imaging (e.g., CT scan with reversed halo sign), microscopy, culture, and histopathology.
- Initial treatment for high-suspicion cases involves liposomal amphotericin B (LAmB) at a dose of at least 5 mg/kg/day combined with surgical debridement.
- For stable disease, treatment is switched to posaconazole (200 mg four times daily); antifungal combination therapy is considered for disease progression.
Main Results:
- The proposed diagnostic approach integrates various methods to ensure accurate identification.
- Liposomal amphotericin B is the preferred initial therapy for severe cases, despite potential nephrotoxicity.
- Posaconazole serves as a step-down therapy for stable disease, with combination therapy as an option for progression.
Conclusions:
- A systematic approach combining rigorous diagnostics with prompt, aggressive treatment is essential for improving outcomes in mucormycosis.
- Early recognition and management, including surgical intervention and appropriate antifungal therapy, are key to combating this life-threatening infection.
- The presented pathways offer a practical framework for clinicians managing immunocompromised patients at risk for mucormycosis.
Related Concept Videos
01:29Fungal Group Zygomycota
2.1K
Zygomycota, previously classified as a distinct fungal group, are primarily terrestrial, saprophytic molds that play a crucial role as decomposers. Recent phylogenetic studies have revealed that these fungi are now divided into two major clades — Mucoromycota, which includes many symbiotic species, and Zoopagomycota, which primarily consists of parasitic and pathogenic fungi. These groups exhibit distinct ecological roles and reproductive strategies while sharing key structural and...
2.1K
01:15Antifungal Agents
119
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
119